[Comment] CYCLONE 2: no impact on prostate cancer forecast

Androgen receptor pathway inhibitors (ARPIs) in combination with androgen deprivation therapy (ADT) represent the foundation of treatment for both metastatic castration-sensitive prostate cancer (mCSPC) and metastatic castration-resistant prostate cancer (mCRPC).1 In selected patients with mCSPC, the addition of six cycles of docetaxel further enhances overall survival outcomes.2 However, therapeutic resistance remains common and prostate cancer remains a substantial cause of cancer-related mortality.